1188264-78-9

Usage

Uses

Used in Pharmaceutical Research and Development:
Tert-butyl 3-Hydroxy-4-methylpiperidine-1-carboxylate is used as a key intermediate in the synthesis of various pharmaceuticals and biologically active compounds. Its presence in the molecular structure of these compounds contributes to their therapeutic properties and efficacy.
Used in Organic Synthesis:
In the field of organic synthesis, tert-butyl 3-Hydroxy-4-methylpiperidine-1-carboxylate is employed as a valuable building block for the creation of complex organic molecules. Its reactivity and functional groups enable the formation of diverse chemical entities with potential applications in various industries.
Used in Neurological Disorders Treatment Research:
Tert-butyl 3-Hydroxy-4-methylpiperidine-1-carboxylate is used as a potential therapeutic agent in the treatment of neurological disorders. Its ability to modulate neurotransmitter levels in the brain has shown promise in the development of novel treatments for such conditions.
Used in the Synthesis of Novel Chemical Entities:
In the pursuit of discovering new pharmacological activities, tert-butyl 3-Hydroxy-4-methylpiperidine-1-carboxylate is utilized as an intermediate in the synthesis of novel chemical entities. Its unique properties and reactivity contribute to the exploration of new therapeutic agents and potential breakthroughs in medicine.

Upstream product

• 24211-54-9 (S)-5-hydroxypiperidin-2-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 384338-20-9 (rac, trans)-1-benzyl-4-methyl-piperidin-3-ol 
• 374822-48-7 C₆H₁₃NO 
• 176966-86-2 tert-butyl (3S,4R)-3-(tert-butyldiphenylsilyloxy)-4-methyl-piperidine-1-carboxylate 
• 1188264-78-9 rac-tert-butyl (3S,4R)-3-hydroxy-4-methylpiperidine-1-carboxylate 
• 1188264-78-9 (rac, cis)-3-hydroxy-4-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 374794-74-8 (trans)-3-hydroxy-4-methyl-piperidine hydrochloride 
• 81474-43-3 (4R,5S)-5-(hydroxymethyl)-4-methyldihydrofuran-2(3H)-one 
• 88424-25-3 methyl (±)-(3-oxiran-2-yl)butanoate 
• 65371-40-6 trans-γ-iodomethyl-β-methyl-γ-butyrolactone 
• 75371-78-7 3-methyl-pent-4-enoic acid 
• 374822-48-7 C₆H₁₃NO 
• 179685-91-7 (4S,5S)-5-azidomethyl-4-methyl-4,5-dihydro-2(3H)-furanone 

Downstream Products

• 374794-77-1 tert-butyl 4-methyl-3-oxopiperidine-1-carboxylate 
• 1188264-78-9 (rac,cis)-3-Hydroxy-4-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 1188264-78-9 (-)-3-hydroxy-4-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 1188264-78-9 (rac, cis)-3-hydroxy-4-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 37835-47-5 rac-(3S,4R)-1,4-dimethylpiperidin-3-ol 
• 477600-74-1 tert-butyl (3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate 
• 1259404-17-5 tasocitinib 

Relevant academic research and scientific papers

Synthesis of key intermediate for (+)-tofacitinib through CoIII(salen)-catalyzed two stereocentered hydrolytic kinetic resolution of (±)-methyl-3-(oxiran-2-yl)butanoate

An enantiopure piperidine, a key intermediate for the synthesis of (+)-tofacitinib, has been achieved in high optical purity (98% ee) from readily available crotyl alcohol. The key steps involved is a CoIII(salen)-OAc-catalyzed two stereocentered hydrolytic kinetic resolution of (±)-methyl-3-(oxiran-2-yl)butanoate.

Asymmetric total synthesis of Tofacitinib

A novel stereoselective synthesis of Tofacitinib (CP-690,550), a Janus tyrosine kinase (JAK3) specific inhibitor, has been achieved starting from (5S)-5-hydroxypiperidin-2-one in 10 steps from 2 with a 9.5% overall yield. The potentiality of this synthetic route is the obtention of tert-butyl-(3S,4R)-3- hydroxy-4-methylpiperidine-1-carboxylate (6b) as a new chiral precursor involved in the synthesis of CP690,550, in a three-step reaction, without epimerizations, rather than the 5 or more steps used in described reactions to achieve this compound from analogues of 6b.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9, and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.

DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS

The invention is concerned with novel bicyclic compounds of Formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9 and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y1, Y2, Y3, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I): wherein A, X, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and may be used as medicaments.

HETEROCYCLIC COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y, R3, R4, R5, R6, R7, R8, R9, R10, m and n are as herein defined, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

Cyclohexyl derivatives and their use as therapeutic agents

The present invention relates compounds of the formula (I): wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of: (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l) and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R?17, R18, R19, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.

Cyclohexane derivatives and their use as therapeutic agents

The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R17, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.

Synthesis of homochiral piperidine derivatives from S-glutamic acid. Stereoselective 1,4-addition of organocuprates to a Δ3-piperidine-2-one. A paroxetine analogue

Enantiomerically pure S-5-hydroxy-2-piperidinone 4, readily available from S-glutamic acid, serves as a key intermediate for the synthesis of 3,4-trans substituted piperidine derivatives. The substituents in the 4-position are introduced via 1,4-conjugate